Loading...
XSTO
SYNACT
Market cap84mUSD
Jun 16, Last price  
16.60SEK
1D
-1.31%
1Q
1.78%
Jan 2017
198.19%
IPO
229.43%
Name

SynAct Pharma AB

Chart & Performance

D1W1MN
P/E
—
P/S
—
EPS
—
Div Yield, %
—
Shrs. gr., 5y
21.67%
Rev. gr., 5y
%
Revenues
0k
Net income
-82m
L-61.82%
-937,000-982,000-15,455,945-15,395,165-23,445,381-23,957,721-26,551,000-69,304,000-99,205,000-215,810,000-82,401,000
CFO
-89m
L-10.96%
00-14,733,613-17,201,772-24,214,950-16,123,518-33,239,000-64,997,000-117,555,000-100,177,000-89,197,000

Profile

SynAct Pharma AB, through its subsidiary, SynAct Pharma ApS, develops medicines for acute deterioration in inflammatory diseases. The company is developing AP1189, a drug candidate for the treatment of rheumatoid arthritis and idiopathic membranous glomerulonephritis. It has a partnership with the University Of Örebro to study the reduction of inflammation in vascular disease. The company was founded in 2012 and is headquartered in Lund, Sweden.
URL
https://synactpharma.com/
IPO date
Jul 11, 2016
Employees
5
Domiciled in
SE
Incorporated in
SE

Valuation

Title
SEK in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
Cost of revenue
89,804
139,759
106,742
Unusual Expense (Income)
NOPBT
(89,804)
(139,759)
(106,742)
NOPBT Margin
Operating Taxes
8,424
(8,466)
(7,860)
Tax Rate
NOPAT
(98,228)
(131,293)
(98,882)
Net income
(82,401)
-61.82%
(215,810)
117.54%
(99,205)
43.14%
Dividends
Dividend yield
Proceeds from repurchase of equity
59,459
228,945
BB yield
Debt
Debt current
595
579
1,000
Long-term debt
3,167
695
3,128
Deferred revenue
Other long-term liabilities
8,304
8,820
(1,000)
Net debt
(57,447)
(61,167)
(104,207)
Cash flow
Cash from operating activities
(89,197)
(100,177)
(117,555)
CAPEX
Cash from investing activities
370
27
Cash from financing activities
87,405
53,984
200,712
FCF
(104,434)
(111,885)
(115,771)
Balance
Cash
61,209
62,395
108,245
Long term investments
46
90
Excess cash
61,209
62,441
108,335
Stockholders' equity
(567,191)
(470,386)
(268,319)
Invested Capital
791,544
656,029
395,353
ROIC
ROCE
EV
Common stock shares outstanding
39,533
32,524
27,585
Price
Market cap
EV
EBITDA
(89,804)
(64,423)
(105,724)
EV/EBITDA
Interest
294
Interest/NOPBT